Top-quality, rapidly growing European stocks are selling at enticing valuations
Timothy Lewis, portfolio manager at JPMorgan European Growth & Income tells us where he’d put his money
The JPMorgan European Growth & Income trust seeks to invest in quality businesses at attractive valuations. By this, we mean well-run companies that produce strong and sustainable returns on invested capital, where earnings per share translate to tangible cash flow, and also those with management teams making sensible decisions with their capital.
One of the most important attributes we look for in companies is improving operational momentum. One way to assess this is by tracking management guidance and earnings-per-share expectations to see whether they are being upgraded or downgraded over time.
In this regard, Europe provides a rich opportunity, thanks to extreme valuation discounts relative to US peers, the much-improved quality of the firms in our index and the strengthening macroeconomic backdrop. Below are three long-standing holdings in the trust, firms that have displayed strong operating momentum for some time and should be able to continue that performance in the future.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A monumental medical leap forward
Novo Nordisk (Copenhagen: NOVO-B) is unique in the pharmaceuticals sector in that it has been almost completely focused on insulin and diabetes for more than a hundred years. It has leveraged its strength in diabetes care into a leading position in the interrelated issue of obesity. Obesity has posed significant challenges for medical practitioners worldwide. Despite advances in healthcare, effective treatment options for obesity have been limited, often culminating in surgical interventions as a last resort.
However, the introduction of Novo Nordisk’s pioneering new drug Wegovy represents a monumental leap forward in the realm of weight-loss treatments. With efficacy levels comparable to surgical procedures, but with significantly reduced risks, Wegovy has emerged as a game-changer in the fight against obesity. Patients’ interest in this revolutionary new drug has continued to exceed expectations, leading to strong operating momentum for the business, but with a market opportunity that can justify sustained growth.
As interest rates have normalised over the past few years, Italy’s UniCredit (Milan: UCG) has experienced an expansion in net-interest margins. This uptrend has resulted in frequent upgrades to earnings forecasts, supporting the sector’s robust performance amid changing market conditions. But valuations for banks such as UniCredit remain compelling, offering an attractive entry point for investors.
Furthermore, thanks to strong capital positions, banks are able to return cash to shareholders through dividends and share buybacks. This shareholder-friendly approach underscores UniCredit’s commitment to delivering long-term value and solidifies its position as an enticing opportunity within the banking sector.
Pioneering Publicis
Ten years ago, Publicis (Paris: PUB) began a journey to lead the advertising industry in data and technology, which included two large acquisitions, Epsilon and Sapient. That journey hasn’t been without bumps in the road, with Covid, a challenging macro-environment and the integration of these two acquisitions to navigate.
However, Publicis is now in a stronger position and has emerged into a much more supportive economic backdrop. It has elevated itself into a “transformation partner” that is data-driven and puts technology first, and which is better able to meet clients’ needs and win market share. Publicis is now the standout leader in the field and looks set to continue that growth.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Tim Lewis, Executive Director, is a portfolio manager within the J.P. Morgan Asset Management International Equity Group, based in London. He has a particular focus on core Europe mandates. An employee since 2013, Tim joined the firm as a graduate trainee. He obtained a BA in Business and Economics at Trinity College Dublin, and an MSc in Behavioural Economics from the University of Nottingham and is a CFA charterholder.
-
Most affordable cities for single homebuyers revealed
Buying a home by yourself? Analysis by Zoopla reveals the most affordable cities in the UK
By Ruth Emery Published
-
How Meta’s shares are thriving in adversity - will 'remarkable' streak continue?
Despite big shake-ups to its Magnificent Seven colleagues, Meta’s shares have been on one of the best winning streaks in stock market history
By Dan McEvoy Published
-
Three companies that dominate their markets with critical products
A professional investor tells us where he’d put his money. This week: Charlie Huggins, manager of Wealth Club’s Quality Shares Portfolio, picks three stocks.
By Charlie Huggins Published
-
Should you continue to hold Smithson Investment Trust?
Opinion Smithson Investment Trust, a small- and mid-cap fund, has struggled to live up to lofty expectations, says Rupert Hargreaves.
By Rupert Hargreaves Published
-
Primark owner Associated British Foods is an overlooked gem going cheap — should you buy shares?
Associated British Foods, the owner of Primark, is a family-owned business, which means it is passed over by the increasingly popular passive investment funds. That spells opportunity for private investors, says Jamie Ward.
By Jamie Ward Published
-
Trump's tariffs and a shrinking market for alcohol deal double blow to Diageo
Donald Trump's tariffs are a further headache for drinks giant Diageo, which is already being buffeted by a decline in alcohol consumption.
By Dr Matthew Partridge Published
-
Three stocks in recruitment companies with promising recovery plays
Recruitment agency Robert Walters and its peers are struggling, but now's the time to buy, says Rupert Hargreaves
By Rupert Hargreaves Published
-
Four UK data companies to buy now
Companies that create, harness or turn data into a valuable offering could be sitting on a hugely profitable gold mine. Rupert Hargreaves picks four of the best UK data companies to buy now.
By Rupert Hargreaves Published
-
What’s the outlook for the shipping industry in 2025?
All we know for certain about the year ahead is that it will be volatile. But the container shipping sector thrives on choppy waters
By Rupert Hargreaves Published
-
Why Wise could be worth a lot more than its share price implies
Foreign-exchange transfer service Wise has the potential to become the Amazon of its sector – here's why you should consider buying this stock now
By Jamie Ward Published